Myeloma Minute: Research Award Winners Announced
December 10, 2015
Generous Donations Help Fund 2016 Brian D. Novis Research Grants
The IMF awarded its 2016 Brian D. Novis research grants in a ceremony Dec 5, 2015 at the 57th annual meeting of the American Society of Hematology (ASH) in Orlando, FL. For 20 years, the IMF has funded promising clinical investigators in the field of multiple myeloma. These grants are made possible through the generous donations of private individuals and IMF Member Fundraisers held across the country. Read more HERE.
Triple Drug Combination Beats Standard Treatment in Myeloma Trial
The addition of bortezomib to a standard two-drug regimen for myeloma patients significantly lengthened the time before their cancer returned, and significantly lengthened their lives, according to clinical trial results presented at ASH by IMF Chairman Dr. Brian Durie. The randomized, phase 3 trial, conducted by SWOG, a publicly funded international cancer clinical trials network, compared the effectiveness of two drug regimens in patients undergoing their first round of treatment for myeloma. “Using bortezomib in combination with lenalidomide and dexamethasone in frontline treatment--hitting the disease early and hard–makes a meaningful difference for myeloma patients," said Dr. Durie. "Our results represent a potential new standard of care.” Watch a video interview with Dr. Durie HERE. Watch IMF interviews with myeloma experts from 2015 ASH HERE.
Extra, Extra, Read All About it! Myeloma Support Group Leaders Share News form ASH 2015
The IMF unleashed 15 patient advocates from around the country on the largest hematological cancer meeting of the year in Orlando, FL, last week. The result? These tireless and passionate myeloma Support Group Leaders not only blogged and tweeted the most important myeloma news, they also helped to earn the IMF a perch among the Most Influential on Twitter. Read their eyewitness reports all in one place on the IMF website HERE.
Top Myeloma Experts Weigh in on MRD, New Drugs and More
We've divided Monday's exciting live-streamed IMWG Conference Series program, Making Sense of Treatment, into four topics. To view them, click on the links below:
*MRD Testing: Is it Ready for Prime Time?
*Frontline Therapy: What Are the Best Options in 2015/16?
*Relapse: How Do You Prioritize New Choices?
*New Agents: Which Are Best and How Do We Assess Them?
We Would Like to Thank Our Sponsors: Takeda, Celgene, Amgen, and Bristol-Myers Squibb